Comerica Bank Has $472,000 Position in Xencor, Inc. (NASDAQ:XNCR)

Comerica Bank grew its holdings in Xencor, Inc. (NASDAQ:XNCR) by 12.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 20,527 shares of the biopharmaceutical company’s stock after purchasing an additional 2,219 shares during the quarter. Comerica Bank’s holdings in Xencor were worth $472,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Sterling Capital Management LLC grew its position in Xencor by 732.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,040 shares in the last quarter. KBC Group NV grew its position in Xencor by 26.0% during the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 813 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Xencor by 49.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock worth $93,000 after buying an additional 1,337 shares in the last quarter. Summit Investment Advisors Inc. grew its position in Xencor by 22.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 1,282 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its position in Xencor by 132.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,865 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 4,482 shares in the last quarter.

Insider Activity at Xencor

In other Xencor news, EVP Nancy Valente sold 4,616 shares of Xencor stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $11.03, for a total transaction of $50,914.48. Following the completion of the sale, the executive vice president now owns 49,169 shares of the company’s stock, valued at approximately $542,334.07. The trade was a 8.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.76% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on XNCR shares. Barclays decreased their target price on Xencor from $22.00 to $6.00 and set an “underweight” rating on the stock in a research report on Thursday, May 8th. Wedbush reissued an “outperform” rating and set a $31.00 target price on shares of Xencor in a research report on Wednesday, April 30th. William Blair initiated coverage on shares of Xencor in a research note on Monday, April 21st. They set an “outperform” rating for the company. Wells Fargo & Company cut their price target on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Finally, StockNews.com cut shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. Two equities research analysts have rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $29.50.

Xencor Stock Performance

Shares of Xencor stock opened at $8.20 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The firm has a market cap of $583.45 million, a P/E ratio of -2.56 and a beta of 0.99. The firm has a 50 day simple moving average of $10.29 and a 200 day simple moving average of $17.30. Xencor, Inc. has a fifty-two week low of $7.16 and a fifty-two week high of $27.24.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.06). The company had revenue of $32.73 million during the quarter, compared to analyst estimates of $23.44 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business’s revenue for the quarter was up 104.6% on a year-over-year basis. During the same period in the prior year, the business earned ($1.11) EPS. Sell-side analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.